Company intelligence
CAMP4 Therapeutics
Advancing a pipeline of ASO-based, RNA-targeting therapeutics with the aim to restore healthy protein levels
About CAMP4 Therapeutics
At CAMP4 Therapeutics, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Join us at the forefront.
Verified activity
Signals from CAMP4 Therapeutics
4 published signals
Presence & Recognition
CAMP4 Therapeutics is hosting a virtual Analyst Day on September 28 from 12:00–1:30 PM ET to share updates on its regRNA-targeting approach for SYNGAP1 and its Phase 1/2 clinical trial.
Reported by CAMP4 Therapeutics
Research & Knowledge
CAMP4 Therapeutics CMO Yuri Maricich MD joined Jessica Brazill in a recent Rareatives article discussing the path toward developing the first potential treatment for SYNGAP1-related disorder.
Reported by CAMP4 Therapeutics
Presence & Recognition
CAMP4 Therapeutics is hosting 1x1 meetings during the Wells Fargo 21st Annual Healthcare Conference in Boston and participating in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York.
Reported by CAMP4 Therapeutics
Presence & Recognition
CAMP4 Therapeutics CSO Dan Tardiff joined Benjamin McLeod and Jeff Martin on The Biotech Voyager podcast to highlight their regRNA-targeting approach using antisense oligonucleotides to modulate gene expression.
Reported by CAMP4 Therapeutics